High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma

BACKGROUND & AIMS: We elucidated the clinical and immunologic implications of serum IL-6 levels in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Ate/Bev). METHODS: We prospectively enrolled 165 patients with unresectable HCC (discovery cohor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hannah, Kang, Beodeul, Ha, Yeonjung, Lee, Sung Hwan, Kim, Ilhwan, Kim, Hyeyeong, Lee, Won Suk, Kim, Gwangil, Jung, Sanghoon, Rha, Sun Young, Gaillard, Vincent E., Cheon, Jaekyung, Kim, Chan, Chon, Hong Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972403/
https://www.ncbi.nlm.nih.gov/pubmed/36866388
http://dx.doi.org/10.1016/j.jhepr.2023.100672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972403/
https://www.ncbi.nlm.nih.gov/pubmed/36866388
http://dx.doi.org/10.1016/j.jhepr.2023.100672

Ejemplares similares